- Automated, Mid-volume Analyzer in CELL-DYN(R) Family Brings Flexibility, Convenience to Hematology Laboratories - ABBOTT PARK, Ill., July 19 /PRNewswire-FirstCall/ -- Today Abbott announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its automated, mid-volume hematology instrument, CELL-DYN Ruby(TM). With its advanced laser optics, this instrument offers enhanced cellular analysis and greater efficiency for laboratories performing complete blood counts (CBCs), a test routinely ordered by doctors to assess a patient's overall health and to screen for a variety of disorders such as anemia and infection. A key facet of CELL-DYN Ruby is its use of laser light to differentiate cellular components. Known as Multi-Angle Polarized Scatter Separation (MAPSS(TM)), this all-optical technology provides detailed results in easy-to-view diagrams, visually depicting changes in white blood cells, red blood cells and platelets. CELL-DYN Ruby also underwent a multi-center medical evaluation showing clinically equivalent results with CELL-DYN Sapphire(TM), a higher-volume, automated analyzer introduced about this time last year. To streamline inventory and simplify laboratory operations, CELL-DYN Ruby only requires four reagents. Additionally, the instrument utilizes advanced yet intuitive software with online tutorials to help facilitate training. "First pass efficiency has been a hallmark of the CELL-DYN family of analyzers and an important part of improving patient care by providing hematology results quickly," said Harold Flynn, divisional vice president and general manager, hematology, Abbott. "CELL-DYN Ruby further enhances our instrument portfolio by bringing a premium, mid-volume analyzer to support the needs of small to medium-sized hospital laboratories and clinics." Abbott's full line of automated hematology instruments includes the CELL-DYN Sapphire, CELL-DYN Ruby, CELL-DYN(R) 3700, CELL-DYN(R) 3200, CELL-DYN(R) 1800 and CELL-DYN(R) SMS(TM) [Slide Maker Stainer]. About CELL-DYN Abbott's CELL-DYN family of hematology instruments is well known for their efficiency and ability to provide fast access to patient results. Instruments range from larger analyzers that process a high number of patient samples to smaller instruments designed for medium and small-volume facilities. Besides supplying standard CBC results, some instruments have additional features to aid in the evaluation of more complex disease states or infections including cancer, HIV and a variety of anemias. About Abbott Diagnostics Abbott Diagnostics is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, blood banks, physician offices and clinics. With more than 65,000 institutional customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnosis from an art to a science through the company's commitment to improving patient care and lowering costs. The history of Abbott Diagnostics is filled with examples of first-of-a-kind products and significant technological advancements. About Abbott Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com/. DATASOURCE: Abbott CONTACT: Media: Jim Schwartz, +1-847-937-3932, or Financial Community: John Thomas, +1-847-935-9390, both of Abbott Web site: http://www.abbott.com/ Company News On-Call: http://www.prnewswire.com/comp/121546.html

Copyright